Literature DB >> 9189688

Oral antifungal drug interactions.

H I Katz1, A K Gupta.   

Abstract

The recent approval of itraconazole and terbafine for the treatment of onychomycosis has launched a new era in the therapeutic management of this previously resistant form of dermatomycoses. These agents represent safe and effective treatments. The clinician should, however, become knowledgeable with the potential drug interactions that are discussed in this article.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9189688     DOI： 10.1016/s0733-8635(05)70460-5

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN： 0733-8635            Impact factor:   3.478


  6 in total

Review 1.  Fact versus Fiction: a Review of the Evidence behind Alcohol and Antibiotic Interactions.

Authors:  Kari A Mergenhagen; Bethany A Wattengel; Megan K Skelly; Collin M Clark; Thomas A Russo
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

Review 2.  A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis.

Authors:  A K Gupta; N H Shear
Journal:  Drug Saf       Date:  2000-01       Impact factor: 5.606

Review 3.  Pharmacokinetics of antifungal agents in onychomycoses.

Authors:  D Debruyne; A Coquerel
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  Activity of TDT 067 (terbinafine in Transfersome) against agents of onychomycosis, as determined by minimum inhibitory and fungicidal concentrations.

Authors:  Mahmoud Ghannoum; Nancy Isham; Jacqueline Herbert; William Henry; Sam Yurdakul
Journal:  J Clin Microbiol       Date:  2011-03-16       Impact factor: 5.948

Review 5.  Onychomycosis in Patients with Diabetes Mellitus in Africa: A Global Scoping Review, 2000-2021.

Authors:  Bassey E Ekeng; Winnie Kibone; Asa E Itam-Eyo; Felix Bongomin
Journal:  Mycopathologia       Date:  2022-09-03       Impact factor: 3.785

Review 6.  Drug interactions of lipid-altering drugs.

Authors:  H E Bays; C A Dujovne
Journal:  Drug Saf       Date:  1998-11       Impact factor: 5.606
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.